Citadel Advisors’s OncoSec Medical ONCS Stock Holding History
Bought
Maintained
Sold
Other funds holding ONCS
SM
Citadel Advisors's ONCS Position: Q4 2022 in Review
Citadel Advisors sold out of OncoSec Medical (ONCS) in Q4 2022, closing a stake of 711 shares — an estimated $8K sold.
Citadel Advisors first reported a position in ONCS in Q1 2017 and held it in 16 quarters. The position peaked at $86K in Q1 2021. 17 funds tracked by Wall St. Rank hold ONCS as of Q4 2022.
- Citadel Advisors reported no remaining OncoSec Medical position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 711 OncoSec Medical shares in Q4 2022, an estimated $8K.
- Citadel Advisors first reported a position in OncoSec Medical in Q1 2017 and held it in 16 quarters.
- Citadel Advisors's OncoSec Medical position peaked at $86K in Q1 2021.
- 17 funds tracked by Wall St. Rank held OncoSec Medical as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.